Monitor for SC451 IND filing and SG293 initial clinical data later this year, as these are the key near-term catalysts. The $160.5M cash position provides runway into mid-2027, but the ATM program may continue to dilute common shareholders. The Mayo Clinic collaboration and $25M investment add credibility to the non-immunosuppressive islet cell approach but do not change the risk profile of a pre-revenue biotech.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 11 $3.79entry
- T+1 · 3mo ago −0.53%α −0.78% · $3.77
- T+5 · 3mo ago −4.22%α −3.82% · $3.63
- T+20 · 2mo ago −16.36%α −15.30% · $3.17
- T+60 · 13d ago −32.45%α −31.97% · $2.56
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Sana Biotechnology reported Q2 2026 GAAP net loss of $63.6M ($0.22/share), slightly narrower than the year-ago $93.8M loss ($0.39/share), driven by the absence of a $44.6M impairment and lower R&D spend. Non-GAAP net loss per share was $0.13, comparing favorably to $0.16 a year ago. The company ended Q2 with $160.5M cash, projecting runway into mid-2027 after raising $93.3M from ATM sales and Mayo Clinic equity investment. Key pipeline catalysts remain on track: SC451 IND/Phase 1/2 start for type 1 diabetes as early as this year, and first-in-human data for SG293 in non-Hodgkin lymphoma also expected this year.
Key Financial Metrics
Key Facts
- Q2 2026 GAAP net loss $63.6M ($0.22/share) vs $93.8M ($0.39/share) in Q2 2025
- Non-GAAP net loss $39.7M ($0.13/share) vs $38.9M ($0.16/share) a year ago
- Cash, equivalents, and marketable securities $160.5M as of June 30, 2026; cash runway expected into mid-2027
- Raised $93.3M in Q2 from ATM sales of common stock and Mayo Clinic equity investment
- SC451 (iPSC-derived islet cell therapy for type 1 diabetes) IND and Phase 1/2 trial start expected as early as 2026
- SG293 (CD8-targeted fusosome for non-Hodgkin lymphoma) first-in-human data expected as early as 2026
- Mayo Clinic invested $25.0M in connection with strategic collaboration for SC451
- NEJM publication of 14-month UP421 data showing survival and function of HIP-modified islet cells without immunosuppression
- R&D expenses $30.7M (Q2 2026) vs $29.8M (Q2 2025), up modestly on program advancement
- Non-cash fair value adjustment on success payments and contingent consideration totaled $23.9M expense in Q2 2026
Financial Impact
No reported revenue; cash burn $69.3M in H1 2026 vs $79.0M in H1 2025; cash position $160.5M with runway to mid-2027 after $93.3M raise
Risk Factors
- Pre-revenue clinical-stage biotech with no approved products; continued operating losses and cash burn
- SC451 and SG293 are in early/preclinical stages; clinical trial outcomes are highly uncertain
- ATM equity sales dilute existing shareholders; further dilution likely given cash runway only to mid-2027
- Contingent consideration and success payment liabilities ($175.3M total) may fluctuate with stock price and program milestones
- Dependence on contract manufacturers and CDMOs for clinical supply; any manufacturing delays could push back timelines
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3342190 |
Track record
12 reports on SANA
3 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +13.50% at T+20 after the May 11, 2026 report. 3 of 5 went positive at some point.
Filters
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $2.37 Now $1.88 −20.68% settles Dec 7
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $2.34 Now $1.88 −19.66% settles Dec 4
- Aug 10, 202614w ago 8-K Neutral 5/10 No price data
- Aug 10, 202614w ago Press Release Neutral 4/10 Viewing Entry $3.79 to $3.17 Now $1.88 −50.40% ▼ −16.36% −15.30% vs SPY
- May 11, 202627w ago 8-K Neutral 4/10 No price data
- May 11, 202627w ago Press Release Bearish 6/10 Entry $3.26 to $2.82 Now $1.88 +42.33% ▲ +13.50% +11.77% vs SPY
- Apr 24, 202629w ago DEFA14A Neutral 4/10 Entry $3.29 to $3.15 Now $1.88 −42.86% ▼ −4.26% −8.28% vs SPY
- Apr 24, 202629w ago 8-K Neutral 2/10 Entry $3.29 to $3.15 Now $1.88 −42.86% ▼ −4.26% −8.28% vs SPY
- Apr 13, 202631w ago 8-K Bullish 6/10 Entry $3.48 to $3.56 Now $1.88 −45.98% ▲ +2.30% −4.00% vs SPY
- Apr 13, 202631w ago Press Release Bullish 7/10 Entry $3.48 to $3.56 Now $1.88 −45.98% ▲ +2.30% −4.00% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers